Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FSHR | P23945 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393499 | 0.82 | ALPL (0.40) | DGAT1ALPLPDGFRBKDRKMT2A | |
| SCHEMBL12772940 | 0.82 | NPC1 (0.51) | NPC1RAB9ADGAT1MGLLFAAH | |
| SCHEMBL16929664 | 0.81 | ALPL (0.44) | DGAT1ALPLPDGFRBKDRHIF1A | |
| SCHEMBL395849 | 0.81 | NPC1 (0.52) | NPC1RAB9ATACR3MGLLFAAH | |
| SCHEMBL5785397 | 0.81 | NPC1 (0.47) | NPC1RAB9ATACR3MGLLFAAH | |
| SCHEMBL31480254 | 0.80 | NPC1 (0.46) | NPC1RAB9ATACR3MGLLMAOB | |
| SCHEMBL3513930 | 0.79 | ALPL (0.44) | DGAT1ALPLPDGFRBKDRHIF1A | |
| SCHEMBL29789810 | 0.79 | POLB (0.51) | NPC1RAB9ADGAT1PDGFRBKDR | |
| SCHEMBL28822828 | 0.79 | POLB (0.51) | NPC1RAB9ADGAT1PDGFRBKDR | |
| SCHEMBL15116265 | 0.78 | NPC1 (0.46) | NPC1RAB9ADGAT1MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150328227-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150328227-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-11-19 | — | — | US | disclosed |
| US-9145393-B2 | Arylpyridinone ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145393-B2 | Arylpyridinone ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112847-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-1831168-B1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | VERTEX PHARMA (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-7786130-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786130-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1919906-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1831168-A1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | Vertex Pharmaceuticals Incorporated (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007027729-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027729-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006065946-A1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, IRAK2 | NPC1 4121/4885RAB9A 4066/4885DGAT1 3955/4885 |
| US-20150328227-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, IRAK2 | NPC1 4121/4885RAB9A 4066/4885DGAT1 3955/4885 |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | NPC1 3761/4885RAB9A 2776/4885DGAT1 4494/4885 |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | NPC1 3807/4885RAB9A 2870/4885DGAT1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.